LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Clostridioides difficile Contamination Uncovered in Clinical Lab

By LabMedica International staff writers
Posted on 01 Aug 2019
Image: A photomicrograph of Gram stain of toxigenic Clostridioides difficile from a stool sample (Photo courtesy of the University of Washington).
Image: A photomicrograph of Gram stain of toxigenic Clostridioides difficile from a stool sample (Photo courtesy of the University of Washington).
Clostridioides (formerly Clostridium) difficile infection is one of the most common hospital-acquired (nosocomial) infections and is an increasingly frequent cause of morbidity and mortality among older adult hospitalized patients. C. difficile is a spore-forming, Gram-positive anaerobic bacillus that produces two exotoxins: toxin A and toxin B.

C. difficile colonizes the human intestinal tract after the normal gut flora has been disrupted (frequently in association with antibiotic therapy) and is the causative organism of antibiotic-associated diarrhea and pseudomembranous colitis. C. difficile infection has traditionally considered to be transmitted predominantly within healthcare settings. C. difficile is not recognized as a pathogen that presents a risk of laboratory acquisition.

A team of scientists collaborating with the staff at the Hospital General Universitario Gregorio Marañón (Madrid, Spain) screened laboratory surfaces for C. difficile. Samples were taken in areas that handle C. difficile isolates (high-exposure areas), areas adjacent to high-exposure HE areas or those processing fecal samples (medium exposure areas), and areas that do not process fecal samples or C. difficile isolates (low exposure areas). They also examined C. difficile carriage (hands/rectal samples) of laboratory workers.

The team collected a total of 140 environmental samples from two high-exposure areas (n = 56), two medium exposure areas (n=56), and two low exposure areas (n = 28). Overall, 37.8% (37/98) of surfaces were contaminated with C. difficile, and 17.3% (17/98) with toxigenic C. difficile. High-exposure areas were significantly more contaminated with toxigenic C. difficile than low exposure areas (38.1% [16/42] versus 0.0% [0/14]) and medium exposure areas (38.1% [16/42] versus 2.4% [1/42]). Hands were colonized with toxigenic C. difficile in 11.8% (4/34) of cases. They found no rectal carriage of C. difficile.

The authors concluded that they had found a significant proportion of laboratory surfaces to be contaminated with toxigenic C. difficile, as well as hand colonization of laboratory personnel. They recommend specific control measures for high-risk areas and laboratory personnel working in these areas. The study was published on July 5, 2019, in the journal Clinical Microbiology and Infection.

Related Links:
Hospital General Universitario Gregorio Marañón

New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more